# Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

> **NCT06475755** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 178 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Anti Angiogenesis

## Interventions

- **DRUG:** Immunochemotherapy combined with antiangiogenic
- **DRUG:** Immunochemotherapy

## Key facts

- **NCT ID:** NCT06475755
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-30
- **Primary completion:** 2025-06-10
- **Final completion:** 2027-12-31
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475755, "Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06475755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*